Bladder Cancer Trial, Recruiting (NCT05825950)

Bladder Cancer Trial, Recruiting NCT05825950 Sponsor: University of Texas Southwestern Medical Center Condition: Bladder Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05825950 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Bladder Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with intermediate or high-risk bladder cancer that has not grown into the deep muscle wall of the bladder (confirm with trial site for exact category details)
You have received treatment placed directly into the bladder (such as BCG, mitomycin C, or gemcitabine/docetaxel) within the last 6 months
You speak and read English or Spanish
You are 18 years of age or older
You are able to understand the study and are willing to sign a consent form agreeing to participate

Who may not be able to join:

There was not enough tissue collected during your bladder surgery (TURBT) to be examined properly
Your bladder cancer has grown into the deeper muscle layer of the bladder or beyond
You are currently receiving cancer treatment that works throughout your whole body (such as chemotherapy or immunotherapy taken by mouth or through a vein)
You are unable to read or write in English or Spanish
You are unwilling to sign a written consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yair Lotan, MD, University of Texas Southwestern Medical Center

Phone: 214-645-8791

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05825950

Sponsor: University of Texas Southwestern Medical Center

Phase: Not Applicable

Status: Recruiting

Condition: Bladder Cancer

Trial contact: 214-645-8791

More information: https://clinicaltrials.gov/study/NCT05825950

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with intermediate or high-risk bladder cancer that has not grown into the deep muscle wall of the bladder (confirm with trial site for exact category details)
You have received treatment placed directly into the bladder (such as BCG, mitomycin C, or gemcitabine/docetaxel) within the last 6 months
You speak and read English or Spanish
You are 18 years of age or older
You are able to understand the study and are willing to sign a consent form agreeing to participate

Who may not be able to join:

There was not enough tissue collected during your bladder surgery (TURBT) to be examined properly
Your bladder cancer has grown into the deeper muscle layer of the bladder or beyond
You are currently receiving cancer treatment that works throughout your whole body (such as chemotherapy or immunotherapy taken by mouth or through a vein)
You are unable to read or write in English or Spanish
You are unwilling to sign a written consent form

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Texas Southwestern Medical Center

Registry

ClinicalTrials.gov

Start date

25 January 2024

Est. completion

1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Recurrence free survival (RFS) at 3 months after TURBT in participants with HR NMIBC; Recurrence free survival (RFS) at 6 months after TURBT in patients with HR NMIBC; Recurrence free survival (RFS) at 12 months after TURBT in patients with HR NMIBC; Recurrence free survival (RFS) at 24 months after TURBT in patients with HR NMIBC

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov